Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity

Science

Volumn 340, Issue 6128, 2013, Pages 71-75

  Kim, Jin Hyo ^a,g   Resende, Ricardo ^a   Wennekes, Tom ^a,h   Chen, Hong Ming ^a   Bance, Nicole ^b   Buchini, Sabrina ^a,i   Watts, Andrew G ^c   Pilling, Pat ^d   Streltsov, Victor A ^d   Petric, Martin ^e   Liggins, Richard ^f   Barrett, Susan ^d   McKimm Breschkin, Jennifer L ^d   Niikura, Masahiro ^b   Withers, Stephen G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c University of Bath   (United Kingdom)

^d CSIRO   (Australia)

^e PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^f Center for Drug Research and Development   (Canada)

^g National Institute of Animal Science   (South Korea)

^h WAGENINGEN UNIVERSITY   (Netherlands)

ⁱ Nano Bridging Molecules SARte Cité Ouest 2   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR; ZANAMIVIR; 2,3 DIFLUOROSIALIC ACID; 2,3-DIFLUOROSIALIC ACID; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

DISEASE SEVERITY; ENZYME; ENZYME ACTIVITY; INFLUENZA; SUBSTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; IC 50; IN VITRO STUDY; INFLUENZA A (H3N2); INFLUENZA VIRUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INACTIVATION; VIRUS MUTANT; VIRUS PLAQUE; VIRUS REACTIVATION; VIRUS STRAIN; WILD TYPE; ANIMAL; CHEMISTRY; DOG; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; MDCK CELL; ORTHOMYXOVIRUS; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANIMALIA;

ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DOGS; ENZYME INHIBITORS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PROTEIN CONFORMATION; SIALIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; ZANAMIVIR;

MLCS; MLOWN;

EID: 84876313858     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1232552     Document Type: Article

References (22)

1. M. von Itzstein et al., Nature 363, 418 (1993).
2. J. L. McKimm-Breschkin et al., J. Virol. 72, 2456 (1998).
3. M. Tashiro et al.; Neuraminidase Inhibitor Susceptibility Network, Antivir. Ther. 14, 751 (2009).
4. M. Kiso et al., Lancet 364, 759 (2004).
5. J. N. Varghese et al., Structure 6, 735 (1998).
6. T. J. Blick et al., Virology 214, 475 (1995).
7. L. V. Gubareva, M. J. Robinson, R. C. Bethell, R. G. Webster, J. Virol. 71, 3385 (1997).
8. A. Eshaghi et al., Emerg. Infect. Dis. 17, 1472 (2011).
9. H. T. Nguyen, A. M. Fry, P. A. Loveless, A. I. Klimov, L. V. Gubareva, Clin. Infect. Dis. 51, 983 (2010).
10. E. van der Vries, F. F. Stelma, C. A. Boucher, N. Engl. J. Med. 363, 1381 (2010).
11. The CAZY Glycoside Hydrolase (GH) database classifies carbohydrate-active enzymes on the basis of sequence similarities. Most bacterial and mammalian sialidases/neuraminidases belong to family GH33.
12. M. von Itzstein, Nat. Rev. Drug Discov. 6, 967 (2007).
13. A. G. Watts et al., J. Am. Chem. Soc. 125, 7532 (2003).
14. M. von Itzstein, B. Jin, W. Y. Wu, M. Chandler, Carbohydr. Res. 244, 181 (1993).
15. See supplementary materials on Science Online for synthesis and characterization.
16. S. L. Newstead et al., J. Biol. Chem. 283, 9080 (2008).
17. S. Barrett, P. G. Mohr, P. M. Schmidt, J. L. McKimm-Breschkin, PLoS ONE 6, e23627 (2011).
18. P. J. Collins et al., Nature 453, 1258 (2008).
19. E. van der Vries et al., PLoS Pathog. 8, e1002914 (2012).
20. L. M. Chavas et al., J. Med. Chem. 53, 2998 (2010).
21. E. G. Brown, H. Liu, L. C. Kit, S. Baird, M. Nesrallah, Proc. Natl. Acad. Sci. U.S.A. 98, 6883 (2001).
22. M. D. Winn et al., Acta Crystallogr. D Biol. Crystallogr. 67, 235 (2011).